Streetbeat News

Analyst Ratings

MCRB

Canaccord Genuity analyst John Newman reaffirms a Buy rating for Seres Therapeutics (NASDAQ:MCRB) and maintains a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 6:38 pm

EXAS

Canaccord Genuity analyst Kyle Mikson has reiterated a Buy rating for Exact Sciences (NASDAQ:EXAS) and maintained a price target of $75.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 6:36 pm

EVTL

Canaccord Genuity has reiterated its Buy rating for Vertical Aerospace (NYSE:EVTL) with a maintained price target of $1.5.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 6:33 pm

COTY

Canaccord Genuity analyst Susan Anderson has reiterated a Buy rating for Coty (NYSE:COTY) and maintained a price target of $14.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 6:29 pm

BNTX

Jefferies analyst Akash Tewari maintains a Hold rating on BioNTech (NASDAQ:BNTX) and raises the price target from $90 to $96.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 6:23 pm

TSLA

Canaccord Genuity analyst George Gianarikas reaffirms a Buy rating on Tesla, maintaining a price target of $254.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 6:13 pm

LOVE

Canaccord Genuity analyst Maria Ripps has reiterated a Buy rating for Lovesac (NASDAQ:LOVE) and maintained a price target of $36.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 6:10 pm

BMRN

Canaccord Genuity analyst Whitney Ijem has maintained a Hold rating on Biomarin Pharmaceutical with a price target of $93.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 6:08 pm

FULC

Fulcrum Therapeutics shares declined following downgrades and reduced price targets from HC Wainwright & Co and RBC Capital.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 6:04 pm

VRSK

Verisk Analytics (NASDAQ:VRSK) has received diverse analyst ratings over the past three months, with a recent increase in average 12-month price targets. Analysts have adjusted their ratings and price targets, reflecting dynamic market conditions and company performance. Verisk's financial performance shows strong profitability and financial health, despite a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 13, 2024 | 6:01 pm